Results 141 to 150 of about 1,330 (154)

Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent

Annals of Pharmacotherapy, 2019
Jason Powell
exaly  

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Blood, 2016
Genmin Lu, , Lu Genmin
exaly  

Andexanet alfa (Ondexxya®)

2020
Glechner, Anna, Zachariah, Casey
openaire   +1 more source

Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy

Journal of Thrombosis and Thrombolysis, 2018
Benilde Cosmi, Michelangelo Sartori
exaly  

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study

Research and Practice in Thrombosis and Haemostasis, 2023
exaly  

Andexanet alfa/apixaban/rivaroxaban

Reactions Weekly, 2019
openaire   +1 more source

Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors

Expert Review of Cardiovascular Therapy, 2017
C Michael Gibson, Yazan Daaboul, Gerald Chi   +2 more
exaly  

Summary of opinion: Ondexxya,andexanet alfa

Case Medical Research, 2019
openaire   +2 more sources

Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban

Journal of Pharmacy Technology, 2019
exaly  

Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors — Individual patient data analysis of ANNEXA-4 and TICH-NOAC

International Journal of Stroke
Martina Goeldlin, Sven Poli, Ashkan Shoamanesh   +2 more
exaly